Medication info
DuoWell Tablets 40/5 mg

DuoWell Tablets 40/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Light yellow oval film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 201405403 · Approved 2014.11.19 · Insurance code 642104620

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with thiazide diuretics such as hydrochlorothiazide, additional blood pressure-lowering effects occur. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. Adjust the maintenance dose appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who require both Telmisartan and Rosuvastatin. Telmisartan primarily helps reduce the risk of myocardial infarction, stroke, and cardiovascular disease-related mortality in patients with essential hypertension and in high-risk groups with a higher risk of cardiovascular disease. Rosuvastatin is used in patients with hypercholesterolemia and dyslipidemia when improvement is not achieved through dietary control, lowering total cholesterol and LDL cholesterol levels to slow the progression of atherosclerosis. It also reduces the risk of stroke, myocardial infarction, and vascular reintervention in middle-aged individuals with elevated high-sensitivity C-reactive protein levels and cardiovascular risk factors. Therefore, this medication is used to protect cardiovascular health and reduce the risk of related complications.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with thiazide diuretics such as hydrochlorothiazide, additional blood pressure-lowering effects occur. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. Adjust the maintenance dose appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.

Precautions

This medication may cause serious harm or death to the fetus if used during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients with a known allergy to this medication or its ingredients, women who are pregnant or may become pregnant, and breastfeeding women should not take this medication. Patients with severely impaired liver function or problems with bile secretion, unexplained elevated liver enzyme levels, or severely impaired kidney function should avoid taking this medication. Patients with a history of muscle disorders or symptoms of myalgia or muscle weakness should be cautious when taking this medication. Elderly patients, patients with elevated potassium levels, mildly impaired liver function, patients with heart disease or gastrointestinal diseases should use this medication with caution. This medication may cause side effects such as myalgia, liver dysfunction, dizziness, or dyspepsia; if any abnormal symptoms occur, consult a doctor immediately. Interactions may occur when taken with other antihypertensive medications or lipid-lowering agents, so be sure to inform any current medications you are taking. It is safest to avoid using this medication during pregnancy or breastfeeding, and particularly for women who may become pregnant, appropriate contraceptive methods should be used. Safety in children has not been established, so its use should be avoided. Caution should be exercised in elderly patients to prevent blood pressure from dropping too low, and dizziness or drowsiness may occur during treatment, requiring attention when driving or operating machinery. In case of overdose, symptoms such as hypotension, impaired kidney function, or myalgia may occur, and immediate medical attention is urged, where treatment will depend on the symptoms. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Elevated ALT, elevated AST, increased serum creatine phosphokinase (CPK), dizziness, itching, dyspepsia, oral paresthesia, musculoskeletal stiffness, acne, nasopharyngitis, dysuria, rhinitis, oral discomfort, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, increased urinary frequency, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, urinary tract infection, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, respiratory distress, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver dysfunction, increased sweating, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, headache, facial spasms, paresthesia, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, hepatic failure, cognitive impairment, severe muscle weakness, ophthalmoplegia, myopathy, myositis, rhabdomyolysis, nausea, palpitations, fatigue, lack of efficacy, numbness, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The storage temperature should be maintained at room temperature between 1°C and 30°C. This helps maintain the medication's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

Light yellow oval film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.